LGND Stock Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
Ligand Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$86.11|
|52 Week High||US$169.98|
|52 Week Low||US$72.57|
|1 Month Change||-6.80%|
|3 Month Change||-4.94%|
|1 Year Change||-36.13%|
|3 Year Change||-15.62%|
|5 Year Change||-39.19%|
|Change since IPO||43.51%|
Recent News & Updates
Ligand Pharmaceuticals: Struggling Along
Summary Ligand Pharmaceuticals is an intriguing but complicated business. The company employs multiple business lines and models under a roof, and at times makes transformative alternations to its business. Fundamental earnings power is fairly limited here, leaving many question marks and uncertainty about potential appeal despite a pullback in the shares.
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Shareholders in Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) may be thrilled to learn that the analysts have...
|LGND||US Biotechs||US Market|
Return vs Industry: LGND underperformed the US Biotechs industry which returned -25.8% over the past year.
Return vs Market: LGND underperformed the US Market which returned -21.5% over the past year.
|LGND Average Weekly Movement||5.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: LGND is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: LGND's weekly volatility (6%) has been stable over the past year.
About the Company
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.
Ligand Pharmaceuticals Fundamentals Summary
|LGND fundamental statistics|
Is LGND overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LGND income statement (TTM)|
|Cost of Revenue||US$109.42m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.47|
|Net Profit Margin||-3.32%|
How did LGND perform over the long term?See historical performance and comparison
Is LGND undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LGND?
Other financial metrics that can be useful for relative valuation.
|What is LGND's n/a Ratio?|
Price to Sales Ratio vs Peers
How does LGND's PS Ratio compare to its peers?
|LGND PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CPRX Catalyst Pharmaceuticals
CDMO Avid Bioservices
LGND Ligand Pharmaceuticals
Price-To-Sales vs Peers: LGND is good value based on its Price-To-Sales Ratio (6x) compared to the peer average (6.7x).
Price to Earnings Ratio vs Industry
How does LGND's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: LGND is good value based on its Price-To-Sales Ratio (6x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is LGND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6x|
|Fair PS Ratio||3.2x|
Price-To-Sales vs Fair Ratio: LGND is expensive based on its Price-To-Sales Ratio (6x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).
Share Price vs Fair Value
What is the Fair Price of LGND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LGND ($86.11) is trading below our estimate of fair value ($217.18)
Significantly Below Fair Value: LGND is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Ligand Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGND is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LGND is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LGND is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LGND's revenue (5.5% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: LGND's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGND's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Ligand Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGND is currently unprofitable.
Growing Profit Margin: LGND is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LGND is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare LGND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGND is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: LGND has a negative Return on Equity (-0.99%), as it is currently unprofitable.
Discover strong past performing companies
How is Ligand Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: LGND's short term assets ($243.8M) exceed its short term liabilities ($167.9M).
Long Term Liabilities: LGND's short term assets ($243.8M) exceed its long term liabilities ($106.1M).
Debt to Equity History and Analysis
Debt Level: LGND has more cash than its total debt.
Reducing Debt: LGND's debt to equity ratio has reduced from 53.4% to 14.3% over the past 5 years.
Debt Coverage: LGND's debt is well covered by operating cash flow (97%).
Interest Coverage: LGND's interest payments on its debt are not well covered by EBIT (1.6x coverage).
Discover healthy companies
What is Ligand Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Ligand Pharmaceuticals Dividend Yield vs Market|
|Company (Ligand Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Ligand Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate LGND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGND's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGND's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LGND has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Higgins (52 yo)
Mr. John L. Higgins serves as Director at OmniAb, Inc. since December 2015 and served as its President since December 2015 until March 2022. Mr. Higgins has been the President and Chief Executive Officer o...
CEO Compensation Analysis
|John Higgins's Compensation vs Ligand Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$10m||US$697k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$6m||US$668k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$7m||US$648k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$6m||US$627k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$6m||US$612k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$5m||US$574k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$5m||US$547k|
Compensation vs Market: John's total compensation ($USD9.59M) is above average for companies of similar size in the US market ($USD5.59M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: LGND's management team is seasoned and experienced (11.4 years average tenure).
Experienced Board: LGND's board of directors are seasoned and experienced ( 11.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LGND insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|16 Sep 22||SellUS$268,060||John Higgins||Individual||3,000||US$90.00|
|13 May 22||BuyUS$206,910||Matthew Foehr||Individual||2,500||US$82.76|
|12 Nov 21||SellUS$481,500||John Higgins||Individual||3,000||US$160.50|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Ligand Pharmaceuticals Incorporated's employee growth, exchange listings and data sources
- Name: Ligand Pharmaceuticals Incorporated
- Ticker: LGND
- Exchange: NasdaqGM
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.454b
- Shares outstanding: 16.88m
- Website: https://www.ligand.com
Number of Employees
- Ligand Pharmaceuticals Incorporated
- 5980 Horton Street
- Suite 405
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LGND||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 1994|
|LGDN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1994|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.